	US 11,939,581 B2
	Methods and compositions for targeting PD-L1
Leonid Beigelman, San Francisco, CA (US); Megan Elizabeth Fitzgerald, San Francisco, CA (US); Saul Martinez Montero, San Francisco, CA (US); and Aneerban Bhattacharya, San Mateo, CA (US)
Assigned to Aligos Therapeutics, Inc., South San Francisco, CA (US)
Filed by ALIGOS THERAPEUTICS, INC., South San Francisco, CA (US)
Filed on Feb. 26, 2021, as Appl. No. 17/249,337.
Claims priority of provisional application 62/983,114, filed on Feb. 28, 2020.
Prior Publication US 2021/0277403 A1, Sep. 9, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01)

CPC C12N 15/1138 (2013.01) [A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); A61P 35/00 (2018.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01)]

18 Claims

1. A small interfering RNA (siRNA) that targets human CD274 mRNA, comprising a sense strand and an antisense strand, wherein the antisense strand comprises nucleotides selected from the group consisting of unmodified nucleotides and modified nucleosides,

wherein each modified nucleoside contains a modified sugar, contains a modified nucleobase or is abasic, or both contains a modified sugar and contains a modified nucleobase or is abasic;

wherein each linkage between the nucleosides is a phosphorothioate, phosphodiester, phosphoramidate, thiophosphoramidate, methylphosphate, methylphosphonate, phosphonoacetate, amide, boranophosphate, or any combination thereof;

wherein the siRNA has a sequence as set forth in any one of SEQ ID NO: 303, and is at least 85% complementary to a fragment of human CD274 mRNA; and

wherein the antisense strand comprises a 5′-phosphate mimic.